Prospective Grant of Exclusive License: The Development of Inmunotoxins as Therapeutics for Focal Muscle Spasms, 49691 [E8-19463]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices
gliomas, lung, breast or prostate cancers
but not in serum from controls.
The correlation between cancer and
BORIS expression indicates that
detection of aberrantly expressed BORIS
and/or anti-BORIS antibodies could
serve as a method of screening or
diagnosing cancer. In patients already
known to have cancer, expression of
BORIS could be monitored to measure
a patient’s response to a particular
therapeutic regimen.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR Part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establish that the grant of
the license would not be consistent with
the requirements of 35 U.S.C. 209 and
37 CFR Part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
which has offices in Vancouver, Canada.
This patent has been assigned to the
Government of the United States of
America. There are no foreign patents or
patent applications associated with this
technology. There are no other U.S.
Patents or Patent Applications
associated with this technology.
The prospective exclusive license
territory may be worldwide, and the
field of use maybe limited to the
development and sale of antibody
conjugated toxins targeting the nicotinic
acetylcholine receptors for therapeutic
treatment of focal muscle spasms, as
claimed in the Licensed Patent Rights.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 21, 2008 will be considered.
ADDRESSES: Requests for copy of the
patent, inquiries, comments, and other
materials relating to the contemplated
exclusive license should be directed to:
Betty B. Tong, PhD, Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 594–6565; Facsimile:
(301) 402–0220; E-mail:
tongb@mail.nih.gov.
Dated: August 14, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–19454 Filed 8–21–08; 8:45 am]
SUPPLEMENTARY INFORMATION:
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: The Development of
Inmunotoxins as Therapeutics for
Focal Muscle Spasms
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
jlentini on PROD1PC65 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(l) and 37 CFR part
404.7(a)(l)(i), that the National Institutes
of Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent license to
practice the invention embodied in
issued U.S. Patent 6,780,413 entitled
‘‘Immunotoxin (MAB–Ricin) for the
Treatment of Focal Movement
Disorders’’ [HHS Ref. E–132–1996/0–
US–04] to Aphrodite Therapeutics, Inc.,
VerDate Aug<31>2005
17:12 Aug 21, 2008
Jkt 214001
The
invention describes immunotoxins and
methods of using the immunotoxins for
the treatment of focal muscle spasms. A
specific immunotoxin covered by this
technology is MAB–Ricin. The
immunotoxins are targeted via an
antibody that is specific to acetylcholine
receptors present in large numbers on
the muscle side of the neuromuscular
junction, allowing the specific
destruction of muscle cells.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
49691
Dated: August 14, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–19463 Filed 8–21–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Strategic Prevention
Framework State Incentive Grant (SPF
SIG) Program (OMB No. 0930–0279)
Revision
SAMHSA’s Center for Substance
Abuse Prevention (CSAP) is responsible
for the evaluation instruments of the
Strategic Prevention Framework State
Incentive Grant (SPF SIG) Program. The
program is a major national initiative
designed to: (1) Prevent the onset and
reduce the progression of substance
abuse, including childhood and
underage drinking; (2) reduce substance
abuse related problems in communities;
and, (3) build prevention capacity and
infrastructure at the State/territory/Tribe
and community levels.
Five steps comprise the SPF:
E:\FR\FM\22AUN1.SGM
22AUN1
]]>Agencies
[Federal Register Volume 73, Number 164 (Friday, August 22, 2008)]
[Notices]
[Page 49691]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-19463]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: The Development of
Inmunotoxins as Therapeutics for Focal Muscle Spasms
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(l) and 37
CFR part 404.7(a)(l)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to practice the invention embodied in
issued U.S. Patent 6,780,413 entitled ``Immunotoxin (MAB-Ricin) for the
Treatment of Focal Movement Disorders'' [HHS Ref. E-132-1996/0-US-04]
to Aphrodite Therapeutics, Inc., which has offices in Vancouver,
Canada. This patent has been assigned to the Government of the United
States of America. There are no foreign patents or patent applications
associated with this technology. There are no other U.S. Patents or
Patent Applications associated with this technology.
The prospective exclusive license territory may be worldwide, and
the field of use maybe limited to the development and sale of antibody
conjugated toxins targeting the nicotinic acetylcholine receptors for
therapeutic treatment of focal muscle spasms, as claimed in the
Licensed Patent Rights.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
October 21, 2008 will be considered.
ADDRESSES: Requests for copy of the patent, inquiries, comments, and
other materials relating to the contemplated exclusive license should
be directed to: Betty B. Tong, PhD, Technology Licensing Specialist,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
(301) 594-6565; Facsimile: (301) 402-0220; E-mail: tongb@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The invention describes immunotoxins and
methods of using the immunotoxins for the treatment of focal muscle
spasms. A specific immunotoxin covered by this technology is MAB-Ricin.
The immunotoxins are targeted via an antibody that is specific to
acetylcholine receptors present in large numbers on the muscle side of
the neuromuscular junction, allowing the specific destruction of muscle
cells.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 14, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-19463 Filed 8-21-08; 8:45 am]
BILLING CODE 4140-01-P
